Defects of CTLA-4 Are Associated with Regulatory T Cells in Myasthenia Gravis Implicated by Intravenous Immunoglobulin Therapy
Myasthenia gravis (MG) is a CD4+ T cell-dependent autoimmune disease resulting from aberrant immune response mediated by circulating autoantibodies at the neuromuscular junction. Intravenous immunoglobulin (IVIg) is an expensive and commonly used immunotherapeutic approach to treat patients with MG....
Saved in:
Main Authors: | Wenhua Xu, Mingshan Ren, Swagata Ghosh, Kai Qian, Zhaofeng Luo, Aimei Zhang, Cuiping Zhang, Jiajun Cui |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2020/3645157 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients
by: Umberto Basile, et al.
Published: (2018-01-01) -
Severe Preeclampsia in the Setting of Myasthenia Gravis
by: Adam J. Lake, et al.
Published: (2017-01-01) -
Myasthenia Gravis Masquerading as Status Asthmaticus
by: Neha Pirwani, et al.
Published: (2021-01-01) -
New treatment options for generalized myasthenia gravis
by: Antanas Vaitkus, et al.
Published: (2024-02-01) -
Autoantibodies in myasthenia gravis: cluster analysis and clinical correlations
by: Xupeng Sun, et al.
Published: (2025-02-01)